ménétrier disease rare acquired premalignant disease stomach characterized massive gastric folds excessive mucous production resultant protein loss little acid production disorder associated excessive secretion transforming growth factor alpha named french physician pierre eugène ménétrier individuals disease present upper abdominal pain epigastric times accompanied nausea vomiting loss appetite edema weakness weight loss small amount gastrointestinal bleeding may occur typically due superficial mucosal erosions large volume bleeding patients depending time presentation develop proteinlosing gastropathy accompanied low blood albumin symptoms pathological features ménétrier disease children similar adults disease children usually selflimited often follows respiratory cause ménétrier disease unknown associated hcmv infection children h pylori infections additionally increased tgfα noted gastric mucosa patients pathophysiology ménétrier disease fully understood thought increase egfr signaling effect increased tfgalpha production responsible inhibition acid production gives rise epithelial cell proliferation mucosa causing direct impact malabsorption nutrients electrolytes vitamins bowel ménétrier disease stomach characterized large tortuous gastric folds fundus body antrum generally spared giving mucosa cobblestone cerebriform brainlike histologically characteristic feature massive foveolar hyperplasia hyperplasia surface glandular mucous glands elongated corkscrewlike appearance cystic dilation common inflammation usually modest although cases show marked intraepithelial lymphocytosis diffuse patchy glandular atrophy evident hypoplasia parietal chief cells although classifies gastritis lamina propria may contain mild chronic inflammatory infiltrate ménétrier disease considered form rather considered one two well understood hypertrophic gastropathies large folds stomach seen ménétrier disease easily detected xray imaging following barium meal endoscopic methods endoscopy deep mucosal biopsy cytology required establish diagnosis exclude entities may present similarly nondiagnostic biopsy may lead surgically obtained fullthickness biopsy exclude cmv helicobacter pylori serology part evaluation twentyfourhour ph monitoring reveals hypochlorhydria achlorhydria chromiumlabelled albumin test reveals increased gi protein serum gastrin levels within normal limits possible causes eg differential diagnosis large folds within stomach include zollingerellison syndrome cancer infection cytomegaloviruscmv histoplasmosis syphilis infiltrative disorders cetuximab firstline therapy ménétrier cetuximab monoclonal antibody epidermal growth factor receptor egfr shown effective treating ménétrier several medications used treatment condition variable efficacy medications include anticholinergic agents prostaglandins proton pump inhibitors prednisone receptor antagonists anticholinergics decrease protein loss highprotein diet recommended replace protein loss patients low levels albumin blood hypoalbuminemia ulcers discovered evaluation treated standard fashion severe disease persistent substantial protein loss despite cetuximab may require total removal stomach especially disease debilitating irretractable high risk developing gastric subtotal gastrectomy performed may associated higher morbidity mortality secondary difficulty obtaining patent longlasting anastomosis normal hyperplastic tissue adults fda approved treatment gastrectomy highprotein diet cetuximab approved compassionate use treatment pediatric cases normally treated symptoms disease clearing weeks months average age onset years men affected often risk gastric adenocarcinoma increased adults ménétrier